The global type 2 diabetes mellitus treatment market size is anticipated to reach USD 91.9 billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030, according to a report by Grand View Research, Inc. This expansion is driven by the increasing global burden of type 2 diabetes and advancements in treatment options. As lifestyle changes, such as poor dietary habits and physical inactivity, contribute to higher obesity rates, the incidence of type 2 diabetes is on the rise. According to the International Diabetes Federation (IDF), over 500 million people worldwide are affected by diabetes, with Type 2 diabetes accounting for approximately 90% of these cases. This growing patient population fuels demand for effective and innovative treatments.
Advancements in diabetes management are boosting market growth. The development of new classes of medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, has significantly improved treatment outcomes. These therapies not only lower blood glucose levels but also offer additional benefits like cardiovascular protection and weight management. The introduction of novel insulin formulations and technologies, including continuous glucose monitors and insulin pumps, further enhances patient care and drives market expansion. For instance, in January 2023, the Food and Drug Administration (FDA) approved Novo Nordisk’s diabetes medication, Rybelsus, as a first-line treatment for lowering blood sugar levels. With this approval, individuals with Type 2 diabetes, in collaboration with their healthcare providers, can now incorporate Rybelsus early in their treatment plan, offering a new option for managing their condition from the onset.
In addition, increasing healthcare investments and improved access to diabetes care contribute to market growth. Governments and healthcare organizations are investing in diabetes management programs, public awareness campaigns, and healthcare infrastructure improvements. These efforts aim to enhance early diagnosis, treatment adherence, and overall patient management.
Request a free sample copy or view report summary: Type 2 Diabetes Mellitus Treatment Market Report
In 2023, the insulin segment accounted for the largest revenue share of 32.8% in diabetes mellitus, type 2 treatment market. This growth primarily is attributed to the rising prevalence of type 2 diabetes around the world due to sedentary lifestyle
Subcutaneous are anticipated to achieve the highest CAGR of 9.4% in the diabetes mellitus, type 2 treatment market during the forecast period
The retail pharmacies segment accounted for the largest revenue share of around 70.0% in diabetes mellitus, type 2 treatment market in 2023
Grand View Research has segmented the global type 2 diabetes mellitus (T2DM) treatment market report based on drug class, route of administration, distribution channel, and region:
Type 2 Diabetes Mellitus Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others
Type 2 Diabetes Mellitus Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Subcutaneous
Intravenous
Type 2 Diabetes Mellitus Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Retail Pharmacies
Hospital Pharmacies
Other
Type 2 Diabetes Mellitus Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Type 2 Diabetes Mellitus Treatment Market
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co. Ltd
Eli Lilly and Co.
Merck & Co. Inc
Novartis AG
Novo Nordisk AS
Sanofi SA
Takeda Pharmaceutical Co. Ltd
"The quality of research they have done for us has been excellent..."